Diagnosis criteria for hypertension
"hypertension" AND "diagnostic criteria"
hypertension diagnosis criteria 2024 guidelines ACC AHA JNC
hypertension diagnosis criteria blood pressure thresholds classification
| BP Category | Systolic BP (mmHg) | Diastolic BP (mmHg) | |
|---|---|---|---|
| Normal | <120 | and | <80 |
| Elevated | 120-129 | and | <80 |
| Stage 1 Hypertension | 130-139 | or | 80-89 |
| Stage 2 Hypertension | ≥140 | or | ≥90 |
- If systolic and diastolic readings fall in different categories, use the higher classification.
- Diagnosis requires an average of ≥2 readings on ≥2 separate occasions.
- Patients on antihypertensive medication are classified as hypertensive regardless of current BP.
| Category | Systolic (mmHg) | Diastolic (mmHg) | |
|---|---|---|---|
| Optimal | <120 | and | <80 |
| Normal | 120-129 | and/or | 80-84 |
| High Normal | 130-139 | and/or | 85-89 |
| Grade 1 Hypertension | 140-159 | and/or | 90-99 |
| Grade 2 Hypertension | 160-179 | and/or | 100-109 |
| Grade 3 Hypertension | ≥180 | and/or | ≥110 |
| Measurement Type | Threshold for Hypertension |
|---|---|
| Office/Clinic BP | ≥140 and/or ≥90 mmHg |
| 24-hour ambulatory (mean) | ≥130 and/or ≥80 mmHg |
| Daytime (awake) ambulatory | ≥135 and/or ≥85 mmHg |
| Nighttime (asleep) ambulatory | ≥120 and/or ≥70 mmHg |
| Home BP monitoring (HBPM) | ≥135 and/or ≥85 mmHg |
| Guideline | Hypertension Threshold |
|---|---|
| ACC/AHA 2017/2025 (USA) | ≥130/80 mmHg (Stage 1) |
| ESC/ESH 2023/2024 (Europe) | ≥140/90 mmHg (Grade 1) |
| JNC 7 (older) | ≥140/90 mmHg |
Amlodipine + valsartan
"amlodipine" AND "valsartan" AND "hypertension"
amlodipine valsartan combination therapy hypertension mechanism clinical evidence
| Rationale | Explanation |
|---|---|
| Complementary mechanisms | CCB dilates via calcium blockade; ARB dilates via RAAS blockade - different pathways with additive BP reduction |
| Edema attenuation | Combining an ARB/ACEi with a CCB reduces CCB-associated peripheral edema by up to 38% (ARBs counteract CCB-induced precapillary dilation by also dilating postcapillary venules, reducing transcapillary pressure gradient) |
| Countering reflex activation | CCBs can trigger reflex renin/Ang II release; ARBs block this compensatory rise |
| Reduced BP variability | CCBs are among the most effective agents for reducing visit-to-visit BP variability, a predictor of stroke and MI |
| RAAS blockade | Protects kidneys and heart independently of BP lowering |
| Amlodipine | Valsartan |
|---|---|
| 5 mg | 160 mg |
| 10 mg | 160 mg |
| 5 mg | 320 mg |
| 10 mg | 320 mg |
| Drug | Key Adverse Effects |
|---|---|
| Amlodipine | Peripheral edema (dose-dependent), headache, flushing, palpitations, reflex tachycardia |
| Valsartan | Hyperkalemia (especially with CKD), hypotension (first dose), dizziness; rarely angioedema, hepatitis, neutropenia |
| Combination | Edema reduced vs. amlodipine alone; hypotension risk; avoid in bilateral renal artery stenosis |
Create a dosing & monitoring protocol document for amlodipine/valsartan therapy
Amlodipine Valsartan Protocol
Word Document · DOCX
| Section | Content |
|---|---|
| Cover Page | Title, version, date, source references |
| 1. Drug Overview | Mechanism of action table (CCB vs ARB), pharmacokinetics comparison, rationale for combination |
| 2. Indications & Contraindications | Approved uses; colour-coded contraindications table (pregnancy, bilateral RAS, dual RAAS blockade, etc.) |
| 3. Dosing Protocol | All 4 Exforge® tablet strengths; standard adult initiation/titration/maximum dose steps; special population table (elderly, CKD, hepatic impairment, pregnancy, breastfeeding, paediatric) |
| 4. BP Targets | 2025 AHA/ACC vs 2024 ESC targets by patient population |
| 5. Monitoring Protocol | Baseline assessment checklist; follow-up schedule (2 weeks → 6 months → annual); critical lab thresholds with specific action triggers |
| 6. Adverse Effects | 10 adverse effects with drug attribution, frequency, and management |
| 7. Drug Interactions | 10 interactions colour-coded by severity (contraindicated / major / moderate) |
| 8. Patient Counselling | Administration, lifestyle modifications (DASH, sodium, exercise, alcohol, smoking), safety warnings |
| 9. Escalation / Referral | 8 clinical scenarios with specific actions including hypertensive emergency |
| 10. References | Guideline + textbook sources with PMIDs |
Which is best to take this medicine at night or morning and with food or without food
"amlodipine" AND "chronotherapy" AND "evening" AND "morning"
amlodipine valsartan best time to take morning or night food effect absorption evidence
morning versus bedtime valsartan amlodipine blood pressure control results
"antihypertensive" AND "bedtime" AND "morning" AND "chronotherapy"
| Scenario | Recommendation |
|---|---|
| General preference | Evening/bedtime (6-10 PM) — modest but real benefit for nocturnal BP |
| If side effects at night (dizziness, hypotension) | Morning is equally acceptable |
| Most important rule | Same time every day - consistency beats "perfect" timing |
| Why nocturnal BP matters | High nighttime BP ("non-dipping pattern") is an independent risk factor for stroke and heart attack, often undertreated |
| Drug | Effect of Food | Recommendation |
|---|---|---|
| Amlodipine | No significant effect on absorption | Take with or without food - your choice |
| Valsartan | Food decreases absorption by ~40% (peak plasma levels reduced) | Best taken on an empty stomach (or consistently the same way each day) |
Take amlodipine/valsartan (Exforge) once daily at bedtime, on an empty stomach (e.g. 9 PM, 2+ hours after dinner). This gives the best nocturnal BP control, takes advantage of amlodipine's peak at 6-12 hours (overnight), and avoids the food interaction with valsartan. If you experience dizziness when standing at night, switch to morning and discuss with your doctor.
If I take 30 minutes before dinner then
| Scenario | Valsartan Absorption |
|---|---|
| Fasting (2+ hours after eating) | Best - full absorption |
| 30 min before a light/moderate meal | Good - acceptable in practice |
| 30 min before a heavy/fatty meal | Moderate - some reduction likely |
| With or right after a meal | Least optimal |
22 may at night before bed 160/110 23 may at night before meal 175/115 24 may at afternoon 170/110 24 may at night before meal 180/120
| Date & Time | SBP | DBP | Category |
|---|---|---|---|
| 22 May – night | 160 | 110 | Stage 2 / Severe |
| 23 May – before meal | 175 | 115 | Stage 2 / Severe |
| 24 May – afternoon | 170 | 110 | Stage 2 / Severe |
| 24 May – night (today) | 180 | 120 | Hypertensive Urgency |
I haven't start any medication yet for bp